- The article analyzes various Hong Kong stock assets, arguing that investors must distinguish between active innovative enterprises and stagnant traditional or defunct entities.
- It highlights that companies like Everest Medicines and Bioland are actively advancing commercialization and product lines, while SaaS and traditional financial firms face shrinking spaces or lack growth narratives.
- It concludes that market participants should direct capital only toward companies with substantive product delivery while abandoning outdated or delisted assets.
